BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBJacobio Pharmaceuticals Group Co. Ltd. out-licensed rights for two lung cancer assets in China to Shanghai Allist Pharmaceuticals Co. Ltd. through a potential ¥900 million... More in BioWorld Asia. Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
China biotechs rise to challenge Ozempic, Wegovy | BioWorld
WEB1 day ago · Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China. At the heart of the GLP-1 boom is a nationwide obesity problem driven by a confluence of factors, including the rise of a modern, sedentary lifestyle, according to Clarivate.
BioWorld: The Daily Biopharmaceutical News Source
WEBBiopharma financings near $78B, almost double last year’s value. Biopharma financing activity surged in the first eight months of 2024, reaching $77.5 billion, a 91.25% increase from the $40.52 billion raised during the same period in 2023. August saw a slight dip in funding, with $3.48 billion raised compared to $3.71 billion in July.
US Biosecure Act a step closer to becoming law | BioWorld
WEB2 days ago · With an eye on shutting down national security threats and securing American innovation, the U.S. House overwhelmingly passed the Biosecure Act Sept. 9 with a vote of 306-81. The next stop on the bill’s path to enactment is a Senate vote and, if it gets that, then on to the president’s desk.
Coronavirus - BioWorld
WEBSep 12, 2024 · The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated: Vaccines and therapeutics in development. Diagnostics with U.S. FDA emergency use authorization.
Exact Sciences presents data to bolster colon cancer test
WEB3 days ago · Exact Sciences Corp. reported performance data for its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by …
China - BioWorld
WEB6 days ago · Sep. 3, 2024. By Marian (YoonJee) Chu. No Comments. Jacobio Pharmaceuticals Group Co. Ltd. out-licensed rights for two lung cancer assets in China to Shanghai Allist Pharmaceuticals Co. Ltd. through a potential ¥900 million (US$126.4 million) deal. Beijing-headquartered Jacobio said Aug. 30 that it …
China - BioWorld
WEBSep. 3, 2024. By Marian (YoonJee) Chu. No Comments. Jacobio Pharmaceuticals Group Co. Ltd. out-licensed rights for two lung cancer assets in China to Shanghai Allist Pharmaceuticals Co. Ltd. through a potential ¥900 million (US$126.4 million) deal. Beijing-headquartered Jacobio said Aug. 30 that it signed off development, regulatory and ...
Today's news in brief | BioWorld
WEBSep 6, 2024 · Today's news in brief. Sep. 6, 2024. BioWorld briefs for Sept. 6, 2024. BioWorld Briefs. Cumulus raising $50M, spinning GPR68 small molecules into GIO. Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up...
ICYMI: Week in review, Sept. 9-13, 2024 | BioWorld
WEB3 days ago · ICYMI: Week in review, Sept. 9-13, 2024. Sep. 16, 2024. A quick look back at top stories. BioWorld. Highfield Biopharmaceuticals files IND in China for immunoliposome HF-50 for solid tumors. Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to conduct a clinical trial ...